Source: Virtual Congress 2020 – Non-tuberculous mycobacteria and latent tuberculosis infection
Disease area: Respiratory infections



Rating:

Share or cite this content

Citations should be made in the following way:
P. Escalante (Rochester, United States of America), V. Van Keulen (Rochester, United States of America), C. Erskine (Rochester, United States of America), T. Peikert (Rochester, United States of America). Non-cytokine activation immunoprofiling to differentiate treatment status in latent tuberculosis infection. 2808

Member's Comments

No comment yet.

Related content which might interest you: Diagnosis and treatment of latent tuberculosis infection Source: Eur Respir Monogr 2018; 82: 381-398 Year: 2018 Our experience of T cell assays in the diagnosis of MTB disease and latent infection Source: Annual Congress 2007 - Gamma-interferon-based tests to diagnose tuberculosis infection and disease Year: 2007 Comparison of effector T-cell responses in patients with active TB disease compared to latent TB infection Source: Annual Congress 2007 - New perspectives and old problems in diagnosing tuberculosis infection and disease Year: 2007 Modulation of QuantiFERON-TB-Gold Plus response in patients with active tuberculosis and latent infection during treatment Source: International Congress 2017 – Migrants and screening Year: 2017 Can we define latent tuberculosis infection? Source: Annual Congress 2003 - Latent tuberculosis infection - preventive approaches Year: 2003 Direct costs of three models for the screening of latent tuberculosis infection Source: Eur Respir J 2006; 28: 45-50 Year: 2006 Cost-effectiveness of interferon-γ release assay testing for the treatment of latent tuberculosis Source: Eur Respir J 2007; 30: 321-332 Year: 2007 Response to Rv2628 latency antigen associates with cured tuberculosis and remote infection Source: Eur Respir J 2010; 36: 135-142 Year: 2010 Expression of the PDCD1 gene to determine active tuberculosis infection in children and adolescents with latent TB infection Source: Virtual Congress 2020 – The young, the old and extrapulmonary tuberculosis Year: 2020 Persistent M. tuberculosis infection: experimental model of endogenously re-activated TB Source: Eur Respir J 2002; 20: Suppl. 38, 582s Year: 2002 Benefit of treatment of latent tuberculosis infection in individual patients Source: Eur Respir J 2016; 47:1592-1594 Year: 2016 Benefit of treatment of latent tuberculosis infection in individual patients Source: Eur Respir J 2015; 46: 1397-1406 Year: 2015 Benefit of treatment of latent tuberculosis infection in individual patients Source: Eur Respir J 2016; 47:1594-1595 Year: 2016 Completion of treatment for latent tuberculosis infection Source: Annual Congress 2011 - Clinical tuberculosis Year: 2011 Interferon-? release assays for the diagnosis of latent Mycobacterium tuberculosis infection Source: Eur Respir J 2011; 38: 1238-1239 Year: 2011 Quantitative scoring of an interferon-γ assay for differentiating active from latent tuberculosis Source: Eur Respir J 2007; 30: 722-728 Year: 2007 How should we treat latent tuberculosis infection? Source: Annual Congress 2003 - Latent tuberculosis infection - preventive approaches Year: 2003 Treatment of latent infection with Mycobacterium tuberculosis: update 2010 Source: Eur Respir J 2011; 37: 690-711 Year: 2011 Diagnosis of latent tuberculosis infection Source: ERS Live 2007 Year: 2007 Combined phenotypical and functional analysis of M. tuberculosis specific immunity for diagnosing active infection and risk assessment in latently infected individuals Source: International Congress 2014 – Future frontiers in the diagnosis of Mycobacterium tuberculosis infection Year: 2014